Inovio outlines late Q4 2027 cash runway as it targets VOCERYQ launch and Europe filing by year-end 2026

Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2026

Management view

• "I'd like to start today's call by highlighting the recent FDA approval of VOCERYQ, formerly known as INO-3107, under the Accelerated Approval Program as a new nonsurgical treatment option to reduce the

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.